King-eagle Med Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 864

Employees

  • Latest Deal Type
  • IPO

  • Financing Rounds
  • 9

King-eagle Med General Information

Description

Provider of one-stop solutions from drug discovery to registration designed for pharmaceutical manufacturing. The company also provides drug research, clinical analysis and testing and drug and material manufacturing, enabling clients with pharmaceutical manufacturing.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • Lugu Technology Industrial Park, Wukuang
  • No. 28, Lutian Road, High-tech Zone
  • Changsha, Hunan 410200
  • China
+86 156
Primary Industry
BPO/Outsource Services
Other Industries
Biotechnology
Drug Discovery
Pharmaceuticals
Corporate Office
  • Lugu Technology Industrial Park, Wukuang
  • No. 28, Lutian Road, High-tech Zone
  • Changsha, Hunan 410200
  • China
+86 156

King-eagle Med Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

King-eagle Med Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore King-eagle Med‘s full profile, request access.

Request a free trial

King-eagle Med Patents

King-eagle Med Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026523332-A Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, its pharmaceutical composition, method of preparation, and its use as an anti-influenza agent. Pending 18-May-2023
EP-4696693-A1 Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof Pending 18-May-2023
US-20260308174-A1 Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof Pending 18-May-2023
WO-2024234474-A1 Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof Inactive 18-May-2023
WO-2023213211-A1 2,4-disubstituted-5-fluoropyrimidine derivative, method for preparing same, and use thereof Inactive 06-May-2022 C07D403/04
To view King-eagle Med’s complete patent history, request access »

King-eagle Med Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

King-eagle Med Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore King-eagle Med‘s full profile, request access.

Request a free trial

King-eagle Med FAQs

  • When was King-eagle Med founded?

    King-eagle Med was founded in 2010.

  • Where is King-eagle Med headquartered?

    King-eagle Med is headquartered in Changsha, China.

  • What is the size of King-eagle Med?

    King-eagle Med has 864 total employees.

  • What industry is King-eagle Med in?

    King-eagle Med’s primary industry is BPO/Outsource Services.

  • Is King-eagle Med a private or public company?

    King-eagle Med is a Private company.

  • What is King-eagle Med’s current revenue?

    The current revenue for King-eagle Med is .

  • How much funding has King-eagle Med raised over time?

    King-eagle Med has raised $41.2M.

  • Who are King-eagle Med’s investors?

    Hunan Heng Chang Pharmaceutical Group, Xiangtan Industrial Investment, Hangzhou Hongcheng Capital, Hunan Djwk Medical, and Hunan Lugu Development Group are 5 of 9 investors who have invested in King-eagle Med.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process